Table 3.
Univariate and multivariate analysis of prognostic factors for PFS in newly diagnosed patients with DLBCL
| Parameters | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Sex (male vs. female) | 1.11 | 0.87–1.42 | 0.408 | ||||
| Age (> 60 vs. ≤60) | 1.16 | 0.90–1.48 | 0.248 | ||||
| Ann Arbor Stage (III–IV vs. I–II) | 2.66 | 1.96–3.60 | < 0.001 | 1.71 | 1.21–2.43 | 0.003 | |
| Extranodal disease (>1 vs. ≤1) | 2.18 | 1.71–2.77 | < 0.001 | 1.49 | 1.14–1.95 | 0.003 | |
| ECOG score (2–4 vs. 0–1) | 2.00 | 1.54–2.60 | < 0.001 | 1.44 | 1.09–1.91 | 0.011 | |
| LDH (>ULN vs. normal) | 2.15 | 1.68–2.75 | < 0.001 | 1.41 | 1.06–1.87 | 0.019 | |
| B symptoms (present vs. absent) | 1.64 | 1.27–2.12 | < 0.001 | 1.13 | 0.85–1.50 | 0.421 | |
| Serum ApoA1 (high vs. low) | 0.62 | 0.48–0.78 | < 0.001 | 0.98 | 0.75–1.29 | 0.902 | |
| Subtype (non-GCB vs. GCB) | 1.76 | 1.33–2.33 | < 0.001 | 1.47 | 1.18–1.84 | 0.001 | |
| Regimen (CHOP-like vs. R-CHOP-like) | 1.58 | 1.16–2.15 | 0.004 | 1.75 | 1.28–2.39 | < 0.001 | |
CI Confidence interval, HR Hazard ratio, ECOG Eastern Cooperative Oncology Group, LDH Lactate dehydrogenase, ULN Upper limit of normal, ApoA1 Apolipoprotein A1, GCB Germinal center B-cell-like